Qiagen snatched up a biomarker from an Austrian research group that will aid in the development of a test designed to better diagnose rare blood disorders.
A harmful gene mutation that increases a woman's risk of developing breast and ovarian cancer may also play a role in brain development, according to new findings by scientists at the Salk Institute for Biological Studies.
Another newly discovered biomarker is now under consideration as a tool to help evaluate and treat disease. When the body expresses it, it appears to be tied to better survival chances in both non-small cell lung cancer and head and neck cancer.
International researchers led by Michigan's Beaumont Health System discovered two biomarkers that helped predict resistance to radiation therapy for patient's with squamous cell cancer of the head and neck.
U.K. researchers have made advances developing a blood test that could screen for patients who have a genetic predisposition to obesity. Their work, published in the journal Diabetes, involves a team from the University of Southampton, University of Exeter Medical School and elsewhere.
A new diagnostic test screens for 5 protein biomarkers that can help differentiate septic shock patients at high or low risk for death. If further testing supports the initial findings, doctors will gain a tool to help them determine which patients need experimental therapies and which should get more traditional treatment.
New research supports the use of a circulating tumor cell blood test, rather than the standard PSA biomarker diagnostic, to predict a patient's odds of surviving prostate cancer.
Two separate research teams say they've made new biomarker discoveries that could help boost early detection and treatment of Alzheimer's disease in different ways.
Australian researchers say they've zeroed in on four new biomarkers that could enable a simple blood test for the early diagnosis of stomach cancer, far earlier and more precise than existing standards of care.
Waters Corp. inked a research partnership deal with an Irish research facility targeted toward developing a blood-based biomarker test that can predict whether a fetus is at high risk for premature birth.